Compound Restores Transparency to Mouse Lenses, Human Lens Tissue
A chemical that could potentially be used in eye drops to reverse cataracts, the leading cause of blindness, has been identified by a team of scientists from UC San Francisco (UCSF), the University of Michigan (U-M), and Washington University in St. Louis (WUSTL).
Identified as a “priority eye disease” by the World Health Organization, cataracts — caused when the lenses of the eyes lose their transparency — affect more than 20 million people worldwide. Although cataracts can be successfully removed with surgery, this approach is expensive, and most individuals blinded by severe cataracts in developing countries go untreated.
Reported November 5 in Science, the newly identified compound is the first that is soluble enough to potentially form the basis of a practical eye-drop medication for cataracts.
Cataracts are primarily a disease of aging. As is seen in neurodegenerative conditions such as Alzheimer’s disease and Parkinson’s disease, a hallmark of the condition is the misfolding and clumping together of crucial proteins. In the case of cataracts, the affected proteins are known as crystallins.
Crystallins are the major component of fiber cells, which form the eyes’ lenses, and the unique properties of these cells make them particularly susceptible to damage, said Jason Gestwicki, PhD, associate professor of pharmaceutical chemistry at UCSF and co-senior author of a paper on the new research, most of which was undertaken in Gestwicki’s laboratory at the U-M Life Sciences Institute.
“Shortly after you’re born, all the fiber cells in the eye lose the ability to make new proteins, or to discard old proteins,” said Gestwicki, who has continued his work on cataracts at UCSF, where he joined the faculty about two years ago. “So the crystallins you have in your eye as an adult are the same as those you’re born with.”
In order for our lenses to function well, this permanent, finite reservoir of crystallins must maintain both the transparency of fiber cells and their flexibility, as the eyes’ muscles constantly stretch and relax the lens to allow us to focus on objects at different distances.
The crystallins accomplish these duties with the help of aptly named proteins known as chaperones, which act “kind of like antifreeze,” Gestwicki said, “keeping crystallins soluble in a delicate equilibrium that’s in place for decades and decades.”
This state-of-affairs is “delicate” because pathological, clumped-together configurations of crystallins are far more stable than properly folded, healthy forms, and fiber-cell chaperones must continually resist the strong tendency of crystallins to clump. A similar process underlies other disorders related to aging, such as Alzheimer’s disease, but in each of these diseases the specific protein that clumps together and the place in the body that clumping occurs is different. In all cases, these clumped-together proteins are called amyloids.
In the new study, led by Leah N. Makley, PhD, and Kathryn McMenimen, PhD, the scientific team exploited a crucial difference between properly folded crystallins and their amyloid forms: put simply, amyloids are harder to melt.
The research group used a method known as high-throughput differential scanning fluorimetry, or HT-DSF, in which proteins emit light when they reach their melting point. At the U-M Life Sciences Institute’s Center for Chemical Genomics, the team used HT-DSF to apply heat to amyloids while applying thousands of chemical compounds.
Because the melting point of amyloids is higher than that of normal crystallins, the team focused on finding chemicals that that lowered the melting point of crystallin amyloids to the normal, healthy range.
The group began with 2,450 compounds, eventually zeroing in on 12 that are members of a chemical class known as sterols. One of these, known as lanosterol, was shown to reverse cataracts in a June paper inNature, but because lanosterol has limited solubility the group who published that study had to inject the compound into the eye for it to exert its effects.
Using lanosterol and other sterols as a clue, Gestwicki and his group assembled and tested 32 additional sterols, and eventually settled on one, which they call “compound 29,” as the most likely candidate that would be sufficiently soluble to be used in cataract-dissolving eye drops.
In laboratory dish tests, the team confirmed that compound 29 significantly stabilized crystallins and prevented them from forming amyloids. They also found that compound 29 dissolved amyloids that had already formed. Through these experiments, said Gestwicki, “we are starting to understand the mechanism in detail. We know where compound 29 binds, and we are beginning to know exactly what it’s doing.”
The team next tested compound 29 in an eye-drop formulation in mice carrying mutations that make them predisposed to cataracts. In experiments conducted with Usha P. Andley, PhD, professor of ophthalmology and visual sciences at WUSTL School of Medicine, they found that the drops partially restored transparency to mouse lenses affected by cataracts, as measured by a slit-lamp test of the sort used by ophthalmologists to measure cataracts in humans.
Similar results were seen when compound 29 eye drops were applied in mice that naturally developed age-related cataracts, and also when the compound was applied to human lens tissue affected by cataracts that had been removed during surgery.
Gestwicki cautions that slit-lamp measures of lens transparency used in the research are not a direct measure of visual acuity, and that only clinical trials in humans can establish the value of compound 29 as a cataract treatment. He has licensed the compound from U-M, however, and Makley, a former graduate student and postdoctoral fellow in the Gestwicki laboratory, is founder and chief scientific officer of ViewPoint Therapeutics, a company that is actively developing compound 29 for human use.
Dogs are also prone to developing cataracts. Half of all dogs have cataracts by nine years of age, and virtually all dogs develop them later in life. An effective eye-drop medication could potentially benefit about 70 million affected pet dogs in the United States.
ViewPoint was formed through the “incubator” program of the California Institute of Quantitative Biosciences (QB3) at UCSF, and is located adjacent to the UCSF campus in QB3’s Janssen Labs.
McMenimen, also a former graduate student in the Gestwicki laboratory, is now the Claire Boothe Luce Assistant Professor of Chemistry at Mt. Holyoke College. The research was supported by the National Institutes of Health, the American Foundation for Pharmaceutical Education, and Research to Prevent Blindness.
In addition to compound 29’s potential for cataract treatment, the insights gained through the research could have broader applications, said Gestwicki, a member of UCSF’s Institute for Neurodegenerative Diseases whose main research interest is dementia and related disorders.
The Latest on: Cataracts
via Google News
The Latest on: Cataracts
- Cataract Surgical Devices Marketon October 8, 2020 at 11:44 pm
To treat cataracts, surgery is performed in which the clouded natural lens is replaced with an artificial lens. The treatment is widely considered to be safe as it is performed using advanced devices ...
- Alcon Celebrates World Sight Day 2020 and Continues Commitment to Improving Worldwide Access to Eye Careon October 8, 2020 at 5:15 am
New Alcon Foundation video PSA highlights the importance of eye health screenings, premiering at this year’s American Academy of Optometry (AAO) annual meeting Alcon (SIX/NYSE: ALC), the global leader ...
- Is there an alternative cure for cataracts?on October 7, 2020 at 5:01 pm
I thought cataracts were associated with much older people. How can I prevent it from spreading too quickly as I plan to work until I'm 65?
- Michael Healy-Rae calls Taoiseach ‘a disgrace’ in fiery row over Kerry TD ‘telling elderly about cataracts outside mass’on October 6, 2020 at 9:38 am
A FURIOUS row erupted in the Dail this afternoon after the Taoiseach accused Michael Healy-Rae of informing elderly people about cataract surgeries outside mass. Micheal Martin claimed he was ...
- LENSAR, Inc. Begins Trading on NASDAQon October 2, 2020 at 7:38 am
--(BUSINESS WIRE)--LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on femtosecond laser surgical solutions for the treatment of ...
- LENSAR, Inc. Begins Trading on NASDAQon October 2, 2020 at 6:30 am
LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on femtosecond laser surgical solutions for the treatment of cataracts, today announced the ...
- Portable new procedure helps doctors remove cataracts in a flashon September 29, 2020 at 3:05 am
Cataracts are an unfortunate part of aging for millions, but a new device is helping doctors remove cataracts with less risk of damaging delicate tissue. Cataracts affect more than 22 million ...
- What does it mean when you have cataracts?on September 24, 2020 at 5:00 pm
Cataracts are cloudy areas that develop in the eye lens. (A healthy lens is clear like a camera's.) Light passes through it to your retina -- the back of your eye where images are processed.
- Barnet Dulaney Perkins Eye Center: Monitoring for cataracts as you ageon September 22, 2020 at 7:59 am
During this time with the COVID-19 pandemic, many people are wondering when it makes sense to think about scheduling their family's routine appointments and wellness checks again. At Barnet ...
- Cataracts Was Topic For Dr. Carey Dozier At Signal Mountain Lions Club Meetingon September 21, 2020 at 5:00 pm
"Cataracts Home and Abroad" was the topic for Dr. Carey Dozier of the East Ridge Eye Center, in his message to the Signal Mountain Lions Club. He illoustrated his remarks with pictures from Nepal.
via Bing News